Cocrystal Pharma – Consensus Indicates Potential 138.7% Upside

Broker Ratings

Cocrystal Pharma found using ticker (COCP) have now 2 analysts in total covering the stock. The consensus rating is ‘Buy’. The range between the high target price and low target price is between 5 and 4.5 calculating the average target price we see 4.75. Now with the previous closing price of 1.99 this would imply there is a potential upside of 138.7%. The day 50 moving average is 1.7 and the 200 day moving average is 1.36. The market capitalisation for the company is $150m. You can visit the company’s website by visiting:

Cocrystal Pharma, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that is in Phase 2a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index